합성생물학 시장 예측(-2030년) : 제품, 기술, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Synthetic Biology Market is accounted for $15.5 billion in 2023 and is expected to reach $52.6 billion by 2030 growing at a CAGR of 19% during the forecast period. Synthetic biology is an advanced field of biology that uses modern science to engineer organisms in order to improve the development of medical and health services. Its applications vary and include cellular signalling, vaccine development, and antibody production. The process includes specific metabolic pathways that are necessary for identifying novel therapeutic targets for the treatment of a variety of illnesses, including infectious, immunological, and cancerous diseases.

According to SynBioBeta data, startups within the synthetic biology sector raised 18.0 billion in 2021.

Market Dynamics:

Driver:

Rising applications of synthetic biotechnology

The funding for synthetic biology research and development has increased due to the growing threat posed by pathogens, pollution, and the climate change crisis. The adoption of synthetic biology has increased in several industries that aim to lower their carbon footprints in order to prevent further rises in global temperatures. This is due to the technology's ability to replicate the properties of essential chemicals and materials without causing negative environmental effects. Therefore, rising research and development in synthetic biology are widening the scope of its applications, which will drive the market.

Restraint:

Bio safety concerns

The intentional or unintentional release of synthetic organisms into the environment for scientific purposes or other purposes poses the main bio safety risk in synthetic biology. When synthetic microorganisms are put into the atmosphere, they can mutate or interact with existing species, resulting in crossbreeding and bio errors. These consequences may endanger the habitats of wild animals. Moreover, a serious threat to bio security is the emergence of viruses that are resistant to antibiotics. These limitations could hamper market expansion in the coming years.

Opportunity:

Expanding applications in healthcare

In drug discovery, synthetic biology accelerates the identification and development of therapeutic compounds by constructing custom biological circuits. This not only enhances the efficiency of drug development but also opens avenues for the creation of more effective and targeted pharmaceuticals. Additionally, synthetic biology plays a crucial role in biopharmaceutical production, enabling the engineering of microorganisms for the synthesis of therapeutic proteins and vaccines. These rising applications in healthcare propel market demand.

Threat:

Limited predictability

The behavior of synthetic organisms and engineered biological circuits often exhibits unpredictability, posing challenges for researchers and developers. The complex interplay of biological components can result in unintended consequences, such as the emergence of unexpected behaviours or the failure of synthetic systems to perform as intended. However, this lack of predictability hinders the efficient design and optimization of synthetic biological systems, leading to time-consuming and resource-intensive trial-and-error approaches. Therefore, limited predictability is a significant element hampering market growth.

COVID-19 Impact

The synthetic biology market saw a minor downturn in growth during the COVID-19 pandemic, at first because of a decrease in production, then lockdown and a labor shortage. However, the market eventually saw resurgence in growth because of the increased need for novel treatments, vaccines, and diagnostics for COVID-19 management. The development of medications and research on the COVID vaccine supported synthetic biology research.

The chassis organism segment is expected to be the largest during the forecast period

The chassis organism segment is estimated to hold the largest share. These chassis organisms provide the essential biological framework onto which genetic circuits and components can be integrated to create novel functionalities or modified biological processes. Bacteria like Escherichia coli and yeasts like Saccharomyces cerevisiae are frequently used chassis organisms. These organisms are selected for their well-understood genetic backgrounds, ease of manipulation, and established tools for genetic engineering. The field's core idea of chassis organisms promotes innovation and developments in synthetic biology.

The PCR technology segment is expected to have the highest CAGR during the forecast period

The PCR technology segment is anticipated to have lucrative growth during the forecast period. Polymerase Chain Reaction (PCR) has evolved as a crucial technology for detecting and analyzing specific gene sequences. For most PCR-based genomic research, real-time PCR tests are the preferred approach due to their exceptional sensitivity and specificity. This approach is commonly utilized in forensic analysis, molecular diagnostics, DNA cloning, and genomics.

Region with largest share:

North America commanded the largest market share during the extrapolated period. The majority of the world's businesses and academic institutions that use synthetic biology in their drug development processes are located in North America. Advances in computer power, artificial intelligence, and genome mapping in this region have prompted researchers to quickly embrace new methods and build upon pre-existing concepts to create new capacities. Additionally, the cooperation of thousands of researchers, scientists, academic institutions, government departments, private investors, and product engineers has advanced the market in this region with new discoveries.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period. Increasing investments in the Asia-Pacific region, more funding and partnerships in the Chinese market, and more collaboration in the field of synthetic biology are some of the factors anticipated to propel market growth. Additionally, Asia is also well-positioned to play a significant role in the application of synthetic biology toward the development of novel therapeutics. Governments and private investors in Asia are becoming increasingly interested in synthetic biology research and technology translation, where the field holds enormous promise for fostering a sustainable bio-based economy.

Key players in the market:

Some of the key players in the Synthetic Biology Market include Synbio Technologies, GenScript, Agilent Technologies, Inc., Eurofins Genomics GmbH, Thermo Fisher Scientific, Amyris, Merck KGaA, Codexis, Inc., Integrated DNA Technologies, Inc., Synthego, EnBiotix, Inc., Genomatica, Inc., New England Biolabs (UK) Ltd. and Scarab Genomics, LLC.

Key Developments:

In April 2022, Merck KGaA Acquisition of MAST Platform from Lonza, a Leading Automated Bioreactor Sampling System. The acquisition of the MAST platform is another milestone to accelerate innovation in Merck's Process Solutions business unit.

In February 2022, Thermo Fisher Scientific announced the launch of GeneMapper Software, a flexible genotyping software package that provides DNA sizing and quality allele calls for all Thermo Fisher Scientific electrophoresis-based genotyping.

Products Covered:

• Oligonucleotide
• Enzymes
• Cloning Technologies Kits
• Synthetic DNA
• Chassis Organism
• Synthetic cells
• Xeno-Nucleic Acids
• Synthetic Clones
• Other Products

Technologies Covered:

• Site-Directed Mutagenesis
• Nanotechnology
• Gene Synthesis
• Bioinformatics
• Measurement and Modelling
• Genome Engineering
• Sequencing
• NGS Technology
• Bio processing
• Cloning
• PCR Technology
• Microfluidics
• Other Technologies

Applications Covered:

• Medical
• Environmental Applications
• Industrial Applications
• Food and Agricultural Applications
• Other Applications

End Users Covered:

• Academics & Research Institutes
• Biotechnology & Pharmaceutical Industry
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Synthetic Biology Market, By Product

• 5.1 Introduction
• 5.2 Oligonucleotide
• 5.3 Enzymes
• 5.4 Cloning Technologies Kits
• 5.5 Synthetic DNA
• 5.6 Chassis Organism
• 5.7 Synthetic cells
• 5.8 Xeno-Nucleic Acids
• 5.9 Synthetic Clones
• 5.10 Other Products

6 Global Synthetic Biology Market, By Technology

• 6.1 Introduction
• 6.2 Site-Directed Mutagenesis
• 6.3 Nanotechnology
• 6.4 Gene Synthesis
• 6.5 Bioinformatics
• 6.6 Measurement and Modelling
• 6.7 Genome Engineering
• 6.8 Sequencing
• 6.9 NGS Technology
• 6.10 Bioprocessing
• 6.11 Cloning
• 6.12 PCR Technology
• 6.13 Microfluidics
• 6.14 Other Technologies

7 Global Synthetic Biology Market, By Application

• 7.1 Introduction
• 7.2 Medical
  • 7.2.1 Drug Discovery and Therapeutics
  • 7.2.2 Pharmaceuticals
  • 7.2.3 Artificial Tissue and Tissue Regeneration
• 7.3 Environmental Applications
  • 7.3.1 Biosensing
  • 7.3.2 Bioremediation
• 7.4 Industrial Applications
  • 7.4.1 Industrial Enzymes
  • 7.4.2 Biofuel and Renewable Energy
  • 7.4.3 Biomaterials and Green Chemicals
• 7.5 Food and Agricultural Applications
  • 7.5.1 Flavors and Fragrances
• 7.6 Other Applications

8 Global Synthetic Biology Market, By End user

• 8.1 Introduction
• 8.2 Academics & Research Institutes
• 8.3 Biotechnology & Pharmaceutical Industry
• 8.4 Other End Users

9 Global Synthetic Biology Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Synbio Technologies
• 11.2 GenScript
• 11.3 Agilent Technologies, Inc.
• 11.4 Eurofins Genomics GmbH
• 11.5 Thermo Fisher Scientific
• 11.6 Amyris
• 11.7 Merck KGaA
• 11.8 Codexis, Inc.
• 11.9 Integrated DNA Technologies, Inc.
• 11.10 Synthego
• 11.11 EnBiotix, Inc.
• 11.12 Genomatica, Inc.
• 11.13 New England Biolabs (UK) Ltd.
• 11.14 Scarab Genomics, LLC